PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26194911-7	2015	In line with this, losartan reduced inflammation and diminished TNF-alpha and IL-6 expression in injured forepaws.	Losartan	19-27	tumor necrosis factor	Mus musculus	64-73	
31535830-9	2019	Atenolol and losartan reversed the upregulation of TNF-alpha expression, whereas enalapril restored IL-6 levels to Sham levels; both atenolol and enalapril normalized IFN-gamma levels.	Losartan	13-21	tumor necrosis factor	Mus musculus	51-60	
21679694-6	2011	More vascular protective effects of telmisartan than losartan were associated with greater anti-inflammatory effects of telmisartan, as shown by attenuation of vascular nuclear factor kappa B (NFkappaB) activation and tumor necrosis factor alpha.	Losartan	53-61	tumor necrosis factor	Mus musculus	218-245	
23727291-4	2013	Treatment with losartan decreased neutrophil recruitment, hypernociception and the production of TNF-alpha, IL-1beta and chemokine (C-X-C motif) ligand 1 in mice subjected to AIA.	Losartan	15-23	tumor necrosis factor	Mus musculus	97-106	
23702425-10	2013	Losartan significantly enhanced IL-4, and decreased IFN-gamma, TNF-alpha and IL-17 (all P<0.05).	Losartan	0-8	tumor necrosis factor	Mus musculus	63-72	
23647130-9	2013	Losartan attenuated the increased serum alanine aminotransferase activity, TNF-alpha and IL-6 levels, and nuclear concentrations of NF-kappaB in I/R.	Losartan	0-8	tumor necrosis factor	Mus musculus	75-84	
25766329-4	2015	Losartan treatment was associated with significantly increased serum tumor necrosis factor alpha (TNF-alpha) level, p65 nuclei accumulation, and decreased muscle IkappaB-beta protein level, indicating NFkappaB activation.	Losartan	0-8	tumor necrosis factor	Mus musculus	69-96	
25766329-4	2015	Losartan treatment was associated with significantly increased serum tumor necrosis factor alpha (TNF-alpha) level, p65 nuclei accumulation, and decreased muscle IkappaB-beta protein level, indicating NFkappaB activation.	Losartan	0-8	tumor necrosis factor	Mus musculus	98-107	
34704526-7	2022	The expression levels of HMGB1, tumor necrosis factor-alpha and interleukin-6 in both the serum and myocardium were upregulated in response to TAC, while they were significantly reduced by losartan.	Losartan	189-197	tumor necrosis factor	Mus musculus	32-59	
18827741-10	2009	Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP.	Losartan	0-8	tumor necrosis factor	Mus musculus	44-53	
18989682-11	2008	Losartan treatment was associated with a significant reduction of the bax-to-bcl-2 ratio and TNF-alpha expression after SBR compared to non-treated groups.	Losartan	0-8	tumor necrosis factor	Mus musculus	93-102	
19540938-5	2009	Moreover, the production of IFN-gamma and TNF-alpha through CTL stimulation can be inhibited by the selective AT1R inhibitor, Losartan.	Losartan	126-134	tumor necrosis factor	Mus musculus	42-51	
33178092-9	2020	Additionally, losartan inhibited pro-inflammatory factor TNF-alpha and improve anti-inflammatory factor IL-10.	Losartan	14-22	tumor necrosis factor	Mus musculus	57-66	
34094856-11	2021	Losartan treatment or PPARgamma activation contributes to reduced levels of IL-6, IL-1beta, TNF-alpha, and COX-2, expression of TGF-beta1, MMP-13, ADAMTS-4, ADAMTS-5, HtrA1, and iNOS, along with reduced Smad2 and Smad3 phosphorylation, but elevated PPARgamma and Collagen II expression in vivo and in vitro.	Losartan	0-8	tumor necrosis factor	Mus musculus	92-101